Drug · CHEMBL701
BACLOFEN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. BACLOFEN. Drugs and targets, record CHEMBL701. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL701
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
- Baclospas-10, Fleqsuvy, Gablofen, Kemstro, Lioresal, Lioresal intrath, Lyflex, Lyvispah, Ozobax, Ozobax ds
- ChEMBL
- Other names
- (rs)-baclofen, BA-34,647, BA-34647, Baclofene, Baclofeno, Fleqsuvy, Lyvispah, NSC-755906
- ChEMBL
- Open Targets' highest stage
- Approval, for 7 of its 40 diseases, from DailyMed, FDA and TTD
- Open Targets
Targets2
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| GABBR1 | GABA-B receptor | GABA-B receptor agonist | AGONIST | https://conductscience.org/library/genes/2550 |
| GABBR2 | GABA-B receptor | GABA-B receptor agonist | AGONIST | https://conductscience.org/library/genes/9568 |
Source ChEMBL
Diseases40
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 40Source Open Targets
See all 40 diseasesTrials112
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01265550 | A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors | Phase 3 | 366 | 2018-02-26 | baclofen | Its name | ClinicalTrials.gov |
| NCT02579759 | Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT) | Phase 3 | 323 | 2020-02-27 | baclofen | Its name | ClinicalTrials.gov |
| NCT03068897 | Ibuprofen Plus Metaxolone, Tizanidine, or Baclofen for Low Back Pain | Phase 4 | 320 | 2020-08-12 | baclofen | Its name | ClinicalTrials.gov |
| NCT00516503 | Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer | Phase 3 | 208 | 2017-08-24 | baclofen | Its name | ClinicalTrials.gov |
| NCT01008280 | Baclofen to Reduce Alcohol Use in Veterans With HCV | Phase 4 | 180 | 2015-06-09 | baclofen | Its name | ClinicalTrials.gov |
| NCT01980706 | Efficacy and Safety of High Dose Baclofen for Alcohol Dependence | Phase 2 | 120 | 2019-01-08 | baclofen | Its name | ClinicalTrials.gov |
| NCT02052440 | Preventing Alcohol Withdrawal Syndrome With Oral Baclofen | Phase 3 | 102 | 2018-03-27 | baclofen | Its name | ClinicalTrials.gov |
| NCT01401257 | Phase II, Randomized, Placebo-controlled Trial in Patients With Charcot-marie-tooth Disease Type 1A | Phase 2 | 80 | 2017-02-16 | baclofen | Its name | ClinicalTrials.gov |
| NCT00597701 | Treating Alcohol Withdrawal With Oral Baclofen | 79 | 2011-07-26 | baclofen | Its name | ClinicalTrials.gov | |
| NCT01002105 | Baclofen as Add-On to Standard Treatment of Alcohol- Dependent Patients | Phase 4 | 75 | 2017-01-27 | baclofen | Its name | ClinicalTrials.gov |
1 to 10 of 112
See all 112 trialsComparisons in its trials23
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Baclofen-amitriptyline Hydrochloride-ketamine vs Placebo: serious adverse events | 1 of 101 | 1 of 102 | 203 | NCT00516503 | Trial comparisons |
| Baclofen vs Placebo: serious adverse events | 6 of 88 | 3 of 92 | 180 | NCT01008280 | Trial comparisons |
| Baclofen 10mg Three Times Daily vs Sugar Pill Given Three Times Daily: deaths from any cause | 0 of 50 | 0 of 51 | 101 | NCT02052440 | Trial comparisons |
| Baclofen 10mg Three Times Daily vs Sugar Pill Given Three Times Daily: Prevention of Progression to Severe Alcohol Withdrawal as Assessed by Severity of Ethanol Withdrawal Score (SEWS). | 13 of 50 | 16 of 51 | 101 | NCT02052440 | Trial comparisons |
| Baclofen 10mg Three Times Daily vs Sugar Pill Given Three Times Daily: serious adverse events | 0 of 50 | 0 of 51 | 101 | NCT02052440 | Trial comparisons |
| Baclofen vs Placebo: serious adverse events | 0 of 32 | 0 of 32 | 64 | NCT01002105 | Trial comparisons |
| ITB-I vs BMT+ITB-NI: deaths from any cause | 1 of 25 | 0 of 35 | 60 | NCT01032239 | Trial comparisons |
| ITB-I vs BMT+ITB-NI: serious adverse events | 12 of 25 | 10 of 35 | 60 | NCT01032239 | Trial comparisons |
| Baclofen vs Placebo: serious adverse events | 2 of 25 | 1 of 19 | 44 | NCT00597701 | Trial comparisons |
| Sugar Pill vs Baclofen: deaths from any cause | 0 of 22 | 0 of 22 | 44 | NCT01821560 | Trial comparisons |
1 to 10 of 23
See all 23 comparisons in its trialsPapers from its trials40
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials11
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Balloon Risk | 1 | 0 | ConductCognition |
| Cancellation Test | 1 | 0 | ConductCognition |
| Delay Discounting | 1 | 0 | ConductCognition |
| Food Cue Reactivity Task | 1 | 1 | ConductCognition |
| Oddball Target Detection | 1 | 0 | ConductCognition |
| Probabilistic Reversal Learning | 1 | 0 | ConductCognition |
| Selective Reminding Task | 1 | 0 | ConductCognition |
| Stop-Signal Task | 1 | 1 | ConductCognition |
| Symbol Coding | 1 | 0 | ConductCognition |
| Trail Making Test A | 1 | 0 | ConductCognition |
1 to 10 of 11
See all 11 tests in its trialsData dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL701
GET https://conductscience.org/api/drugs/v1/CHEMBL701/diseases?page=2